An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

Breastcancer Clinical Trial

Official title:

An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04168957
• Other study ID #: KX-ORAX-008
• Secondary ID: U1111-1180-5217
• Status: Terminated
• Phase: Phase 1
• Start date: October 25, 2017
• Est. completion date: November 12, 2020

Study information

• Verified date: February 2022
• Source: Athenex, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

KX-ORAX-008 is an extension study of patients who completed KX-ORAX-007 without disease progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and who wish to continue Oraxol treatment.

Description:

This is a multicenter, open-label, extension study offering the option of further Oraxol treatment to breast cancer patients who have completed the KX-ORAX-007 Oraxol study with complete response (CR), partial response (PR), or stable disease (SD), and who wish to continue further Oraxol treatment. The study contains 3 periods: the Screening Period, the Treatment Period, and the Follow-up Period. A Final Visit will occur within 7 days of the last dose of study treatment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 11
• Est. completion date: November 12, 2020
• Est. primary completion date: August 27, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Breast cancer patients who have completed Study KX-ORAX-007 without disease progression at Week 16, who wish to continue Oraxol treatment.

2. Signed written informed consent.

3. Willing to fast for 6 hours before and 2 hours after Oraxol administration on all treatment days.

4. Patients must be postmenopausal (>12 months without menses) or surgically sterile (ie, by hysterectomy and/or bilateral oophorectomy) or must be using effective contraception (ie, oral contraceptives, intrauterine device, double barrier method of condom and spermicide) and agree to continue use of contraception for 30 days after their last dose of assigned study treatment.

Exclusion Criteria:

1. Have not recovered from unacceptable toxicity associated with previous Oraxol treatment in KX-ORAX-007.

2. Are currently receiving other medications intended for the treatment of their malignancy.

3. Women who are pregnant or breastfeeding.

4. Taking any following prohibited medications:

• Strong inhibitors (eg, ketoconazole) or strong inducers (eg, rifampin or St. John's Wort) of CYP3A4 (within 2 weeks prior to the start of dosing in the study).
• Strong inhibitors (eg, gemfibrozil) or strong inducers (eg, rifampin) of CYP2C8 (within 2 weeks prior to the start of dosing in the study).
• Strong P-gp inhibitors or inducers.
• An oral medication with a narrow therapeutic index known to be a P-gp substrate (eg, digoxin, dabigatran) within 24 hours prior to start of dosing in the study.

5. Use of warfarin. Patients receiving warfarin who are otherwise eligible and who may be appropriately managed with low molecular weight heparin, in the opinion of the Investigator, may be enrolled in the study provided they are switched to low molecular weight heparin at least 7 days prior to receiving study treatment.

6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, myocardial infarction within the last 6 months, unstable angina pectoris, cardiac arrhythmia, chronic pulmonary disease requiring oxygen, known bleeding disorders, or any concomitant illness or social situation that would limit compliance with study requirements.

7. Known allergic reaction or intolerance to study medication components.

8. Known allergic reaction or intolerance to contrast media.

9. Patients who, in the Investigator's opinion, are not suitable for participation in this study.

Related Conditions & MeSH terms

• Breast Neoplasms
• Breastcancer

Intervention

Drug:
• Oraxol
Oraxol (oral paclitaxel + oral HM30181AK-US) Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets

Locations

Country	Name	City	State
Taiwan	Taipei Medical University Shuang Ho Hospital	New Taipei City
Taiwan	China Medical University Hospital	Taichung city
Taiwan	Taipei Medical University Hospital	Taipei
Taiwan	Tr-Service General Hospital	Taipei
Taiwan	Taipei Veterans Generla Hospital	Taipei, Taiwan, 11217

Sponsors (2)

Lead Sponsor	Collaborator
Athenex, Inc.	PharmaEssentia

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Safety assessments will consist of determining and recording all adverse events and SAEs (adverse events will be graded on a 5-point scale according to CTCAE v4.03); Evaluate the safety of Oraxol. Number of participants with treatment-related adverse events.	From screening until final visit (within 72 hours prior to Day 21 of Study Period 2, preferably before the participant receives any additional chemotherapy)
Secondary	Activity: Tumor response	The number of patients with CR or PR at any post-baseline assessments after the start of treatment in KX-ORAX-007. Computed tomography (CT) and/or magnetic resonance imaging (MRI) scans will be conducted on Day 1 every 8 weeks until documented progression. Tumor status will be evaluated using RECIST v1.1 criteria. In addition to using the RECIST criteria, the Investigator must consider all other clinical information as part of tumor status evaluation.	from the start of treatment in KX-ORAX-007 until follow up visit every 2 months after patient withdrawal up to 10 months.